tiprankstipranks
Advertisement
Advertisement

NMRA Stock Latest News

Ami Fadia Reiterates Buy on Neumora, Sees Compelling Risk-Reward Ahead of Phase 3 Readouts with Unchanged $8 Price Target
RatingsAmi Fadia Reiterates Buy on Neumora, Sees Compelling Risk-Reward Ahead of Phase 3 Readouts with Unchanged $8 Price Target
1d ago
NMRA
Analyst Initiates Buy on Neumora, Citing Compelling Risk/Reward Ahead of Key Navacaprant Readouts and Broader Pipeline Upside
PremiumRatings
Analyst Initiates Buy on Neumora, Citing Compelling Risk/Reward Ahead of Key Navacaprant Readouts and Broader Pipeline Upside
8d ago
NMRA
Neumora Therapeutics reports Q1 EPS (30c), consensus (31c)
PremiumThe Fly
Neumora Therapeutics reports Q1 EPS (30c), consensus (31c)
8d ago
NMRA
Neumora: Deep Pipeline and Near‑Term Clinical Catalysts Support Attractive Risk‑Reward and Buy Rating
PremiumRatings
Neumora: Deep Pipeline and Near‑Term Clinical Catalysts Support Attractive Risk‑Reward and Buy Rating
1M ago
NMRA
Neumora Therapeutics management to meet with Piper Sandler
PremiumThe Fly
Neumora Therapeutics management to meet with Piper Sandler
1M ago
NMRA
Neumora Therapeutics Maps High-Stakes Catalyst Road Ahead
PremiumCompany AnnouncementsNeumora Therapeutics Maps High-Stakes Catalyst Road Ahead
1M ago
NMRA
Neumora Therapeutics Warns Nasdaq Delisting Risk Could Hit Liquidity, Share Price, and Capital Access
Premium
Company Announcements
Neumora Therapeutics Warns Nasdaq Delisting Risk Could Hit Liquidity, Share Price, and Capital Access
2M ago
NMRA
Midday Fly By: Sysco buying Restaurant Depot, Uber to acquire Blacklane
Premium
The Fly
Midday Fly By: Sysco buying Restaurant Depot, Uber to acquire Blacklane
2M ago
IQ
SR
Options Volatility and Implied Earnings Moves Today, March 30, 2026
PremiumMarket News
Options Volatility and Implied Earnings Moves Today, March 30, 2026
2M ago
CBAT
DFDV
Neumora Therapeutics reports Q4 EPS (35c), consensus (33c)
PremiumThe Fly
Neumora Therapeutics reports Q4 EPS (35c), consensus (33c)
2M ago
NMRA
NMRA Earnings this Week: How Will it Perform?
PremiumPre-Earnings
NMRA Earnings this Week: How Will it Perform?
2M ago
NMRA
Neumora Therapeutics management to meet virtually with Needham
PremiumThe Fly
Neumora Therapeutics management to meet virtually with Needham
2M ago
NMRA
Neumora upgraded to Outperform from Market Perform at William Blair
PremiumThe FlyNeumora upgraded to Outperform from Market Perform at William Blair
3M ago
NMRA
Differentiated NMRA-511 Efficacy and Safety in Alzheimer’s Agitation Support Buy Rating on Neumora
Premium
Ratings
Differentiated NMRA-511 Efficacy and Safety in Alzheimer’s Agitation Support Buy Rating on Neumora
3M ago
NMRA
Strengthening NMRA-511 Clinical Profile and Upside Potential Underpin Buy Rating and $18 Target
Premium
Ratings
Strengthening NMRA-511 Clinical Profile and Upside Potential Underpin Buy Rating and $18 Target
3M ago
NMRA
Neumora outlines 2026 neuroscience pipeline and obesity plans
PremiumCompany Announcements
Neumora outlines 2026 neuroscience pipeline and obesity plans
4M ago
8K
NMRA
Diversified CNS Pipeline and NLRP3 Opportunity Drive Upside in Neumora: Justifying an Outperform/Buy Rating
PremiumRatings
Diversified CNS Pipeline and NLRP3 Opportunity Drive Upside in Neumora: Justifying an Outperform/Buy Rating
4M ago
NMRA
Neumora Therapeutics initiated with an Outperform at Leerink
PremiumThe Fly
Neumora Therapeutics initiated with an Outperform at Leerink
4M ago
NMRA
Neumora Therapeutics price target raised to $6 from $5 at Mizuho
PremiumThe Fly
Neumora Therapeutics price target raised to $6 from $5 at Mizuho
4M ago
NMRA
Neumora (NMRA-511): Encouraging Early Alzheimer’s Agitation Data but Mixed V1a History and Valuation Keep Risk-Reward Balanced at Hold
PremiumRatingsNeumora (NMRA-511): Encouraging Early Alzheimer’s Agitation Data but Mixed V1a History and Valuation Keep Risk-Reward Balanced at Hold
4M ago
NMRA
Positive Risk-Reward on Neumora as NMRA-511 Emerges as a Differentiated Therapy for Alzheimer’s Agitation, Supporting Buy Rating and $18 Target
Premium
Ratings
Positive Risk-Reward on Neumora as NMRA-511 Emerges as a Differentiated Therapy for Alzheimer’s Agitation, Supporting Buy Rating and $18 Target
4M ago
NMRA
Neumora reports promising Phase 1b results in Alzheimer’s agitation
Premium
Company Announcements
Neumora reports promising Phase 1b results in Alzheimer’s agitation
4M ago
8K
NMRA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >